Anika Therapeutics reported $87.78M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acorda Therapeutics ACOR:US USD 20.7M 2.43M
Agenus AGEN:US USD 208.35M 20.03M
Agios Pharmaceuticals AGIO:US USD 122.45M 33.91M
Anika Therapeutics ANIK:US USD 87.78M 3.62M
Clovis Oncology CLVS:US USD 58.32M 36.26M
Halozyme Therapeutics HALO:US USD 147.16M 56.23M
Heron Therapeutics HRTX:US USD 50.44M 1.83M
Immunogen IMGN:US USD 309.51M 64.36M
Insmed INSM:US USD 414.63M 1.44M
Integra Lifesciences IART:US USD 511.94M 64.78M
Intrexon XON:US USD 9.07M 34.78M
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Ligand Pharmaceuticals LGND:US USD 121.41M 116.13M
Macrogenics MGNX:US USD 83.99M 62.52M
Merit Medical Systems MMSI:US USD 51.48M 11.52M
Peregrine Pharmaceuticals PPHM:US USD 77.29M 37.84M
Rigel Pharmaceuticals RIGL:US USD 29.87M 2.66M
Sangamo Biosciences SGMO:US USD 94.57M 23.14M
Stryker SYK:US USD 1.84B 424M
Veracyte VCYT:US USD 170.11M 16.66M
Xencor XNCR:US USD 52.65M 3.24M
Zimmer Biomet Holdings Inc ZBH:US USD 375.7M 169.7M